Evidence map›Paper›PMID 41239272›Full record

ReviewBMC cancer2025

Anoikis resistance and cancer.

Steven M Frisch, Gangqin Hu

Abstract readReview
In one paragraph

Review in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Steven M FrischDepartment of Biochemistry and Molecular Medicine, West Virginia University, 64 Medical Center Drive, Campus box 9142, Morgantown, WV, 26506, USA. sfrisch@hsc.wvu.edu.
Gangqin HuDepartment of Microbiology and Immunology, West Virginia University, 64 Medical Center Drive, Morgantown, WV, 26506, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Normal epithelial cells detach from extracellular matrix during normal homeostasis by a selective process called epithelial extrusion. Thereafter, they undergo apoptosis, in a phenomenon called anoikis. Metastatic tumor cells, however, detach from normal epithelial tissues or primary tumors and survive in circulation, sometimes long enough to disseminate and colonize metastatic sites. The thirty years since the discovery of anoikis, exciting progress has been made in understanding anoikis mechanisms and the diverse mechanisms by which tumor cells evade or subvert them. Previous reviews have summarized earlier aspects of anoikis, including integrin-apoptosis signaling, Epithelial-Mesenchymal Transition and intracellular metabolism. Based on recently emerging work, we focus here on four issues that advance our conceptual understanding significantly: How do cytoskeleton and signaling interface so as to control anoikis? How is epithelial extrusion programmed in normal vs. cancer cells, upstream of anoikis? What is the role of translational regulation in anoikis? How do tumor cell-blood cell interactions affect anoikis? This review summarizes recent observations that inform these issues, and provides perspective on future problems to be investigated.

Indexed as

AnoikisNeoplasmsAnimalsCytoskeletonEpithelial-Mesenchymal TransitionHumansSignal TransductionAnoikisApoptosisEpithelial extrusionMechanotransductionTranslational control

Identifiers

PMID41239272
PMCPMC12619527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.